{"id":911511,"date":"2025-11-19T08:03:18","date_gmt":"2025-11-19T13:03:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-issues-letter-to-shareholders-4\/"},"modified":"2025-11-19T08:03:18","modified_gmt":"2025-11-19T13:03:18","slug":"nanovibronix-issues-letter-to-shareholders-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-issues-letter-to-shareholders-4\/","title":{"rendered":"NanoVibronix Issues Letter to Shareholders"},"content":{"rendered":"

<\/p>\n

NanoVibronix Issues Letter to Shareholders<\/b><\/p>\n

ENvue\u00ae Feeding Tube Placement System Identified as Core Growth Platform<\/i><\/p>\n

Strategic Rebranding and Name Change to Reflect Company\u2019s Focus on Multi-Billion-Dollar Enteral-Feeding Market<\/i><\/p>\n

The Company is Considering Strategic Alternatives for Legacy Assets<\/i><\/p>\n

TYLER, Texas–(BUSINESS WIRE<\/a>)–NanoVibronix, Inc. (NASDAQ: NAOV)<\/b> (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today issued a letter to shareholders, highlighting the Company\u2019s strategic vision, market opportunities and a rebranding initiative.<\/p>\n

\nDear Shareholders,<\/p>\n

\nSince assuming the role of CEO in June 2025, our team has completed a comprehensive review of our operations, technologies and market opportunities. Throughout this process, our objective has remained clear: to focus on the opportunities that can deliver the greatest long-term value for shareholders and execute on them successfully. It became clear from this review that our ENvue\u00ae feeding-tube placement system (\u201cENvue\u201d), which was merged into NanoVibronix in early 2025, is our strongest and most scalable growth platform. ENvue is 510(k) FDA-cleared, commercially available and already improving clinical workflows and patient outcomes across U.S. hospitals. By providing real-time anatomical navigation, the system assists clinicians in performing enteral-tube placements with greater confidence and efficiency. We believe that ENvue\u2019s ability to deliver live guidance positions it as a modern solution in a large and growing market. In the U.S. alone, the enteral feeding devices market is projected to reach approximately $1.8 billion by 20301<\/sup>, representing meaningful upside potential.<\/p>\n

Market Opportunity and Strategic Focus<\/b><\/p>\n

\nOur strategy is now focused on scaling hospital utilization, strengthening our commercial footprint and building a comprehensive enteral-feeding ecosystem around ENvue through both internal development and external business development opportunities. The U.S. enteral-feeding market represents a substantial opportunity with more than 5,000 acute care hospitals2<\/sup> nationwide performing thousands of tube placements daily. Many providers continue to rely on outdated methods, creating a meaningful opportunity for ENvue to accelerate revenue growth and become the standard of care across the country. The following new market opportunities highlight ENvue\u2019s potential as a comprehensive navigation platform, enabling expansion across multiple critical-care procedures and driving sustainable, long-term growth for the company:<\/p>\n